Label: OXYTOCIN injection, solution
- NDC Code(s): 61133-6013-2
- Packager: Bimeda, Inc.
- Category: PRESCRIPTION ANIMAL DRUG LABEL
Updated December 13, 2023
If you are a healthcare professional or from the pharmaceutical industry please visit this version.
(purified oxytocic principle)
INJECTION FOR HORSES, COWS, SOWS, & EWES
20 USP Units per mL
Not for Use in Humans
KEEP OUT OF REACH OF CHILDREN
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION: Oxytocin injection is a sterile aqueous solution of highly purified oxytocic principle derived by synthesis or obtained from the posterior lobe of the pituitary gland of healthy domestic animals used for food by humans. Oxytocin injection contains 20 USP Units of Oxytocin and less than 0.4 units of presser activity per mL. Each mL of sterile solution also contains 0.9% w/v sodium chloride, 0.5% w/v chlorobutanol (as a preservative), with water for injection q.s. and pH adjusted to 3.0 to 5.0 with acetic acid.
ACTIONS: Oxytocin acts directly on the smooth musculature of the uterus in all species to induce rhythmic contractions, although in some species the uterine cervix does not respond to oxytocin. The responsiveness of the uterine musculature to oxytocin varies greatly with the stage of the reproductive cycle. During the early phases of pregnancy the uterus is relatively insensitive to the effects of oxytocin, while in the late phases the sensitivity is markedly increased. Most authorities attribute this varying response to the varying levels of estrogen and progesterone during the course of pregnancy. Oxytocin also has been shown to exert a milk ejecting effect, occasionally referred to as the galactogogic effect. The actual mechanism by which oxytocin stimulates the release of milk from the mammary glands is not know with certainty, but oxytocin is presumed to act on certain smooth muscle elements in the gland.
INDICATIONS & USAGE
INDICATIONS: Because of the specific action of oxytocin upon the uterine musculature, it is recommended as an aid in the management of the following conditions:
1. To precipitate labor.2. To accelerate normal parturition.3. Postpartum evacuation of uterine debris.4. Postoperative contraction of the uterus following a cesarean section and control of uterine hemorrhage.
Oxytocin will contract the smooth muscle cells of the mammary gland to induce milk let-down if the udder is in a proper physiological state.
DOSAGE & ADMINISTRATION
DOSAGE AND ADMINISTRATION:
Obstetrical Use: Inject aseptically by the intravenous, intramuscular or subcutaneous route as follows:
1.5 to 2.5mL......................30 to 50 USP Units
5.0mL...............................100 USP Units
These dosages are recommended, and may be repeated as indicated.
Inject aseptically by the intravenous, intramuscular or subcutaneous route
0.5 to 1.0mL.....................10 to 20 USP Units
0.25 to 1.0mL....................5 to 20 USP Units
These dosages are recommended and may be repeated as necessary.
Note: Oxytocin will not induce milk let-down unless the udder is in proper physiological state.
To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.
- HOW SUPPLIED
- STORAGE AND HANDLING
- PRINCIPAL DISPLAY PANEL
INGREDIENTS AND APPEARANCE
oxytocin injection, solution
Product Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:61133-6013 Route of Administration INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength OXYTOCIN (UNII: 1JQS135EYN) (OXYTOCIN - UNII:1JQS135EYN) OXYTOCIN 20 [USP'U] in 1 mL Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:61133-6013-2 100 mL in 1 VIAL Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANADA ANADA200328 05/24/2004 Labeler - Bimeda, Inc. (060492923) Registrant - Bimeda, Inc. (060492923) Establishment Name Address ID/FEI Business Operations Bimeda - MTC Animal Health 256232216 manufacture